All News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
0.758 ^USD	+2.43%		-29.16%	-29.16%

Jun. 04	FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025	CI
May. 28	Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan	Jun. 04	PR
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025	Jun. 04	CI
IceCure Medical : Company Presentation	Jun. 03	PU
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024	May. 29	AQ
Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024	May. 28
Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000	May. 28	MT
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	May. 21	PR
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	May. 20	PR
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	May. 07	PR
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	May. 07	CI
IceCure Medical : Company Presentation	Apr. 23	PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	Apr. 16	AQ
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	Apr. 15	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	Apr. 15	CI
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	Apr. 03	AQ
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024	Apr. 03
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 03	CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	Apr. 02	MT
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	Apr. 02	PR
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	Apr. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News IceCure Medical Ltd

Equities

ICCM

IL0011224156

All News

Filters